Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) [Phase 3]
Phase 3 multicenter trial evaluating the efficacy and safety of VESIcare (solifenacin) for urgency associated with overactive bladder; the s…
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: Solifenacin Succinate Versus Tolterodine 4mg Once Daily [Phase 3]
A Phase 3 study comparing solifenacin succinate to tolterodine 4 mg once daily in adults with overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms [Phase 3]
Open-label Phase 3 study evaluating the efficacy and safety of Vesicare (solifenacin) in patients with overactive bladder; the trial has com…
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) [Phase 4]
A Phase 4 trial comparing adding bladder training to solifenacin versus solifenacin alone in patients with overactive bladder and urge incon…
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms [Phase 3]
Phase 3 clinical trial evaluating Solifenacin succinate 5 mg or 10 mg once daily for urgency symptoms in overactive bladder has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-09-18Clinical Trial Update: A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. [Phase 4]
A Phase 4 trial evaluating solifenacin succinate in combination with tamsulosin for residual overactive bladder symptoms in men has complete…
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder
This clinical trial update reports post-marketing surveillance results of fesoterodine in Filipino patients with overactive bladder, with re…
-
CLINICAL_TRIALS trial_result · 2014-09-11Clinical Trial Update: Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder [NA]
A completed clinical trial assessed the safety and effectiveness of a non-invasive neuromodulation device for urgency urinary incontinence i…
-
CLINICAL_TRIALS trial_result · 2014-09-05Clinical Trial Update: Post Marketing Survey of Vesicare in Japan
A post-marketing survey of Vesicare (solifenacin) conducted in Japan has completed, evaluating safety and usage in patients with overactive …
-
CLINICAL_TRIALS trial_result · 2014-08-19Clinical Trial Update: A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) [Phase 1]
Phase 1 trial assessing tolterodine tartrate for overactive bladder has completed with results posted.
-
FDA approval · 2014-08-13FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2014-07-28FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for tolterodine tartrate from Mylan Pharmaceuticals, marking an approved change related to its label…
-
FDA label_change · 2014-07-28FDA Approved: DETROL LA — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Detrol LA (tolterodine tartrate) submitted by Viatris Specialty LLC, resulting in labeling chang…
-
FDA approval · 2014-07-18FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL (oxybutynin) from Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2014-07-11Clinical Trial Update: Over Active Bladder Instillation Study - Botox [Phase 3]
Phase 3 study of intravesical Botox for overactive bladder was terminated with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-07-10Clinical Trial Update: A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment [Phase 4]
Phase 4 clinical study evaluating the effect of solifenacin on the Overactive Bladder Symptom Score in adults with overactive bladder; the s…
-
CLINICAL_TRIALS trial_result · 2014-06-13Clinical Trial Update: A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis [Phase 3]
Phase 3 long-term follow-up study of botulinum toxin type A for overactive bladder due to spinal cord injury or multiple sclerosis completed…
-
CLINICAL_TRIALS trial_result · 2014-06-04Clinical Trial Update: A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
A pilot sleep-lab trial to observe nocturnal bladder function in subjects with Overactive bladder has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-05-30Clinical Trial Update: Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
An observational study was conducted to estimate the frequency of dry mouth in overactive bladder patients treated with solifenacin.
-
CLINICAL_TRIALS trial_result · 2014-05-23Clinical Trial Update: Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder [Phase 4]
A Phase 4 study evaluating solifenacin with percutaneous tibial nerve stimulation versus placebo for refractory overactive bladder was termi…
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: Behavioral Treatment of Overactive Bladder in Men [Phase 3]
Phase 3 clinical trial update reporting results for behavioral treatment of overactive bladder in men; results were posted after study compl…
-
FDA approval · 2014-05-16FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan, Inc.'s supplemental application for OXYTROL (oxybutynin). This action updates the product's labeling and/or indic…
-
FDA approval · 2014-05-15FDA Approved: OXYTROL FOR WOMEN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL FOR WOMEN (oxybutynin) submitted by Allergan, Inc. This action updates the product's lab…
-
CLINICAL_TRIALS trial_result · 2014-04-21Clinical Trial Update: Botulin-A Toxin Instillations and Overactive Bladder [Phase 1, Phase 2]
A Mayo Clinic-sponsored Phase 1/2 trial evaluated botulinum toxin type A instillations for overactive bladder/detrusor overactivity; results…
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. [Phase 4]
A Phase 4 clinical trial update evaluating two doses of solifenacin succinate in women with overactive bladder has completed and posted resu…